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The long-term view of regenerative medicine therapies predicts an increased need for expansion solutions that 
ease scalability, utilize animal origin-free materials and are compatible with limited downstream processing 
steps. As more cell therapeutics progress through clinical testing, current in vitro culture methods are proving 
cumbersome to scale and lack robustness. Moreover, high quality animal origin-free reagents and downstream 
processing devices support the future implementation of large scale manufacturing solutions that will be 
required following clinical success. Here, we describe the implementation of single use bioreactors and high 
quality media for expansion of cell therapies. We focus on autologous T cells and will review solutions 
addressing animal origin-free expansion of cells within the context of different upstream process development 
steps as well as scaling with good cell quality, high recovery, high viability and good activity. We also compare 
the effect of donor variability on performance. Start to finish solutions for expansion, including high quality 
reagents, are key enabling technologies for success in commercializing cell therapies. 
 
